Heron Therapeutics | HRTX

Stock Price
1.12
Daily Change
0.90%
Yearly
-62.67%
Q2 Forecast
1.09
Rating
Sell

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
Eisai 9,500.00 450.00 4.97% 82.48%
ALKERMES 29.51 0.23 0.79% 0.68%
Alnylam Pharmaceuticals 193.67 5.00 2.65% 47.26%
Amarin 1.28 0.07 5.79% -23.81%
Anika Therapeutics 27.27 0.55 2.06% 22.07%
ANI Pharmaceuticals 48.00 1.58 3.40% 64.16%
Arrowhead Research 36.05 1.38 3.98% 3.41%
Emergent BioSolutions 8.24 0.04 0.49% -74.44%
Endo International 0.03 0 0% -94.89%
Esperion Therapeutics 1.36 0.03 2.26% -76.67%
GlaxoSmithKline 1,367.60 20.00 1.48% -19.32%
Heron Therapeutics 1.12 0.01 0.90% -62.67%
Immunogen 14.37 0.20 1.41% 288.38%
Insmed 19.54 0.30 1.56% 0.05%
Ligand Pharmaceuticals 75.31 4.11 5.77% -11.32%
Merck & Co 112.52 1.59 1.43% 25.15%
Neurocrine Biosciences 92.32 1.13 1.24% -3.37%
Nektar Therapeutics 0.62 0.02 3.08% -82.94%
Omeros 7.41 0.13 1.79% 196.40%
Pacira 39.09 1.05 2.76% -39.22%
Ultragenyx Pharmaceutical 50.85 1.24 2.50% -1.09%
Regeneron Pharmaceuticals 739.95 8.78 1.20% 17.39%
Roche Holding 292.80 3.05 1.05% -8.70%
Sangamo BioSciences 1.15 0.04 3.60% -69.09%
Surmodics 19.02 0.79 4.33% -50.70%
Veracyte 26.72 0.53 2.02% 56.07%
Vertex Pharmaceuticals 333.78 10.16 3.14% 23.88%

Indexes Price Day Year
USND 13241 139.78 1.07% 10.22%
US2000 1831 62.97 3.56% -2.77%

Heron Therapeutics

Heron Therapeutics traded at $1.12 this Friday June 2nd, increasing $0.01 or 0.90 percent since the previous trading session. Looking back, over the last four weeks, Heron Therapeutics gained 51.93 percent. Over the last 12 months, its price fell by 62.67 percent. Looking ahead, we forecast Heron Therapeutics to be priced at 1.09 by the end of this quarter and at 1.00 in one year, according to Trading Economics global macro models projections and analysts expectations.

Heron Therapeutics, Inc. is a biotechnology company. The Company is focused in developing pharmacological agents for patients suffering from pain or cancer. Its oncology care product portfolio consists of SUSTOL and CINVANTI. Its SUSTOL (granisetron) is an extended-release, injectable used in the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy (MEC) or anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. Its CINVANTI, in combination with other antiemetic agents is used in the prevention of acute and delayed nausea and vomiting associated with emetogenic cancer chemotherapy (HEC). The Company's acute care product portfolio consist of ZYNRELEF (HTX-011) HTX-034, and HTX-019. The ZYNRELEF (HTX-011) is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of nonsteroidal anti-inflammatory drug meloxicam.